220P Elacestrant vs fulvestrant or aromatase inhibitor (AI) in phase III trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), vs standard of care (SOC) endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC): Subgroup analysis from EMERALD
| Autor: | Aftimos, P.G., Cortés, J., Bidard, F.C., V. Kaklamani, Bardia, A., Neven, P., Streich, G., Montero, A., Forget, F., Mouret Reynier, M.A., Sohn, J., Taylor, D., Harnden, K., Khong, H., Kocsis, J., Dalenc, F., Dillon, P., Tonini, G., Grzegorzewski, K.J., Lu, J. |
|---|---|
| Zdroj: | In Annals of Oncology September 2022 33 Supplement 7:S638-S638 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|